Dyadic International, Inc. (NASDAQ:DYAI – Get Free Report) was the target of a large decrease in short interest in the month of July. As of July 31st, there was short interest totalling 125,100 shares, a decrease of 10.4% from the July 15th total of 139,600 shares. Based on an average daily trading volume, of 104,800 shares, the days-to-cover ratio is currently 1.2 days. Currently, 0.6% of the company’s stock are short sold.
Institutional Investors Weigh In On Dyadic International
An institutional investor recently bought a new position in Dyadic International stock. Callan Capital LLC bought a new stake in Dyadic International, Inc. (NASDAQ:DYAI – Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 27,174 shares of the biotechnology company’s stock, valued at approximately $45,000. Callan Capital LLC owned 0.09% of Dyadic International at the end of the most recent reporting period. Hedge funds and other institutional investors own 27.95% of the company’s stock.
Dyadic International Stock Up 3.0 %
Dyadic International stock traded up $0.04 during trading on Monday, hitting $1.36. 14,310 shares of the company were exchanged, compared to its average volume of 56,928. The company has a market capitalization of $39.76 million, a P/E ratio of -4.82 and a beta of 0.73. The business’s 50 day moving average is $1.53 and its 200 day moving average is $1.58. Dyadic International has a 52 week low of $1.13 and a 52 week high of $2.67. The company has a current ratio of 5.54, a quick ratio of 5.54 and a debt-to-equity ratio of 1.29.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright restated a “buy” rating and issued a $6.00 target price on shares of Dyadic International in a report on Monday, July 8th.
Get Our Latest Stock Analysis on DYAI
About Dyadic International
Dyadic International, Inc, a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health.
See Also
- Five stocks we like better than Dyadic International
- Earnings Per Share Calculator: How to Calculate EPS
- Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?
- What is the NASDAQ Stock Exchange?
- 2 Option Strategies to Maximize Profits in a Bear Market
- What is a SEC Filing?
- Lululemon Stock Gears Up for a Massive Comeback Rally
Receive News & Ratings for Dyadic International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyadic International and related companies with MarketBeat.com's FREE daily email newsletter.